Contrave
Fat-fighting pharma business files for bankruptcy
March 15, 2018Sales and Marketing Contrave, biotech, drugs, orexigen, pharma, pharmaceutical
Orexigen Therapeutics, a biotech that was one of a wave of companies bringing through weight-loss pills, has announced that it …
Orexigen takes back rights to its weigh management drug from Takeda
March 16, 2016Business Services, Manufacturing and Production, Sales and Marketing Contrave, Orexigen Therapeutics, akeda Pharmaceuticals
Orexigen Therapeutics (Nasdaq: OREX) has taken back the rights to its weight management drug from Japanese pharma giant Takeda Pharmaceuticals …
Orexigen and Takeda reboot Contrave collaboration
August 12, 2015Research and Development Contrave, FDA, Takeda, orexigen, weight loss drugs
Orexigen has agreed to foot the $200 million bill for a new trial to prove its claims that Contrave, the …
Takeda hits major snags with Contrave and Alisertib
May 14, 2015Sales and Marketing Contrave, Takeda, alisertib, obesity, orexigen
Takeda is threatening to end its partnership with Orexigen to market the obesity drug Contrave, as allegations around its heart …
Novo Nordisk obesity drug shows added benefits
March 9, 2015Sales and Marketing (liraglutide), Contrave, Novo Nordisk, Victoza, Xenical, liraglutide, obesity, saxenda, weight
New research by Novo Nordisk has suggested that its obesity drug Saxenda can help improve several other weight-related problems as …
Fourth diet pill makes it to US market
September 11, 2014Manufacturing and Production, Sales and Marketing Contrave, FDA, Orexigen Therapeutics, diet, obesity
Orexigen Therapeutics has gained FDA approval for its new obesity treatment Contrave to help overweight patients reduce their food intake. …
Sanofi to produce weight-loss drug for Orexigen
November 11, 2013Manufacturing and Production, Sales and Marketing Contrave, FDA, Sanofi, orexigen
Sanofi has agreed a deal to manufacture Orexigen Therapeutics’ weight-loss candidate Contrave outside North America. Under the commercial supply agreement, …
Takeda obesity drug falters at phase II
March 18, 2011Research and Development Alli, Amylin, Contrave, Meridia, Qnexa, Takeda, Xenical, lorcaserin, metreleptin, obesity, pramlintide
Yet another investigational drug appears to have faltered on the rocky path to develop anti-obesity treatments. Takeda Pharmaceutical Company and …
